Drug Profile
Research programme: therapeutic cancer vaccines - Eterna Therapeutics/National Cancer Research Center Japan
Latest Information Update: 17 Oct 2022
Price :
$50
*
At a glance
- Originator IRX Therapeutics
- Developer IRX Therapeutics; National Cancer Center (Tokyo)
- Class Vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 17 Oct 2022 Brooklyn ImmunoTherapeutics is now called Eterna Therapeutics
- 07 Nov 2018 IRX Therapeutics has been acquired and merged into Brooklyn ImmunoTherapeutics
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Japan